Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities

Marta Zarandi, Jozsef L. Varga, Andrew V. Schally, Judit E. Horvath, Gabor L. Toller, Magdolna Kovacs, Markus Letsch, Kate Groot, Patricia Armatis, Gabor Halmos

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Antagonists of growth hormone-releasing hormone (GHRH) synthesized previously inhibit proliferation of various human cancers, but derivatisation with fatty acids could enhance their clinical efficacy. We synthesized a series of antagonists of GHRH(1-29)NH2 acylated at the N terminus with monocarboxylic or α,ω-dicarboxylic acids containing six to sixteen carbon atoms. These peptides are analogs of prior potent antagonists JV-1-36, JV-1-38, and JV-1-65 with phenylacetyl group at their N terminus. Several new analogs, including MZ-J-7-46 and MZ-J-7-30, more effectively inhibited GHRH-induced GH release in vitro in a su perfused rat pituitary system than their parent compound JV-1-36 and had increased binding affinities to rat pituitary GHRH receptors, but they showed weaker inhibition of GH release in vivo than JV-1-36. All antagonists acylated with fatty acids containing 8-14 carbon atoms inhibited the proliferation of MiaPaCa-2 human pancreatic cancer cells in vitro better than JV-1-36 or JV-1-65. GHRH antagonist MZ-J-7-114 (5 μg/day) significantly suppressed the growth of PC-3 human androgen-independent prostate cancers xenografted into nude mice and reduced serum IGF-I levels, whereas antagonist JV-1-38 had no effect at the dose of 10 μg/day. GHRH antagonists including MZ-J-7-46 and MZ-J-7-114 acylated with octanoic acid and MZ-J-7-30 and MZ-J-7-110 acylated with 1,12-dodecanedicarboxylic acid represent relevant improvements over earlier antagonists. These and previous results suggest that this class of GHRH antagonists might be effective in the treatment of various cancers.

Original languageEnglish (US)
Pages (from-to)4610-4615
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number12
StatePublished - Mar 21 2006


  • Antagonistic analogs
  • Cancer therapy
  • Proliferation

ASJC Scopus subject areas

  • Genetics
  • General


Dive into the research topics of 'Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities'. Together they form a unique fingerprint.

Cite this